-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 5, the official website of NMPA showed that Hanyu Pharmaceutical's somatostatin for injection passed the consistency evaluation of generic drugs, which was the first domestic company to pass the evaluation
.
According to data from Mi Nei.
com, in 2020, the sales of terminal somatostatin in public medical institutions in China will exceed 2.
4 billion yuan
.
Up to now, Hanyu Pharmaceutical has been evaluated for 7 varieties
.
.
According to data from Mi Nei.
com, in 2020, the sales of terminal somatostatin in public medical institutions in China will exceed 2.
4 billion yuan
.
Up to now, Hanyu Pharmaceutical has been evaluated for 7 varieties
.
Somatostatin is a cyclic polypeptide hormone.
Somatostatin for injection is mainly used for acute esophageal varices bleeding; severe acute gastric or duodenal ulcer bleeding, or complicated with acute erosive gastritis or hemorrhagic gastritis; pancreatic surgery Prevention and treatment of complications after surgery; adjuvant treatment of pancreatic, biliary and intestinal fistulas; adjuvant treatment of diabetic ketoacidosis
.
Somatostatin for injection is mainly used for acute esophageal varices bleeding; severe acute gastric or duodenal ulcer bleeding, or complicated with acute erosive gastritis or hemorrhagic gastritis; pancreatic surgery Prevention and treatment of complications after surgery; adjuvant treatment of pancreatic, biliary and intestinal fistulas; adjuvant treatment of diabetic ketoacidosis
.
Sales of terminal somatostatin in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Menet.
com, in 2020, the sales of terminal somatostatin in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) will exceed 2.
4 billion yuan; in 2021H1, its sales will exceed 1 billion yuan , An increase of 2.
46% year-on-year.
From the perspective of manufacturers, Merck's market share was 35.
8%, Jiangsu Coast Pharmaceuticals accounted for 22.
26%, and Hanyu Pharmaceuticals accounted for 12.
36%
.
com, in 2020, the sales of terminal somatostatin in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) will exceed 2.
4 billion yuan; in 2021H1, its sales will exceed 1 billion yuan , An increase of 2.
46% year-on-year.
From the perspective of manufacturers, Merck's market share was 35.
8%, Jiangsu Coast Pharmaceuticals accounted for 22.
26%, and Hanyu Pharmaceuticals accounted for 12.
36%
.
At present, there are 16 manufacturers of somatostatin for injection in the domestic market, and Hanyu Pharmaceutical is the first company to review this product
.
Five companies including Shandong New Times Pharmaceuticals, Hainan Shuangcheng Pharmaceuticals, Jiangsu Coast Pharmaceuticals, Chengdu Shengnuo Biology, and Shanghai Huayuan Pharmaceuticals have submitted supplementary applications for the consistency evaluation of this product
.
.
Five companies including Shandong New Times Pharmaceuticals, Hainan Shuangcheng Pharmaceuticals, Jiangsu Coast Pharmaceuticals, Chengdu Shengnuo Biology, and Shanghai Huayuan Pharmaceuticals have submitted supplementary applications for the consistency evaluation of this product
.
Up to now, Hanyu Pharmaceutical has passed or deemed to have passed the consistency evaluation of 7 varieties, including Thymofaxine for Injection, Carbetocin Injection, Etibatide Injection, and Pramipexole Hydrochloride Sustained Release Tablets , Metformin hydrochloride sustained-release tablets, trimetazidine hydrochloride sustained-release tablets and somatostatin for injection
.
.
Data source: Mi Neiwang database
On November 5, the official website of NMPA showed that Hanyu Pharmaceutical's somatostatin for injection passed the consistency evaluation of generic drugs, which was the first domestic company to pass the evaluation
.
According to data from Mi Nei.
com, in 2020, the sales of terminal somatostatin in public medical institutions in China will exceed 2.
4 billion yuan
.
Up to now, Hanyu Pharmaceutical has been evaluated for 7 varieties
.
.
According to data from Mi Nei.
com, in 2020, the sales of terminal somatostatin in public medical institutions in China will exceed 2.
4 billion yuan
.
Up to now, Hanyu Pharmaceutical has been evaluated for 7 varieties
.
Somatostatin is a cyclic polypeptide hormone.
Somatostatin for injection is mainly used for acute esophageal varices bleeding; severe acute gastric or duodenal ulcer bleeding, or complicated with acute erosive gastritis or hemorrhagic gastritis; pancreatic surgery Prevention and treatment of complications after surgery; adjuvant treatment of pancreatic, biliary and intestinal fistulas; adjuvant treatment of diabetic ketoacidosis
.
Somatostatin for injection is mainly used for acute esophageal varices bleeding; severe acute gastric or duodenal ulcer bleeding, or complicated with acute erosive gastritis or hemorrhagic gastritis; pancreatic surgery Prevention and treatment of complications after surgery; adjuvant treatment of pancreatic, biliary and intestinal fistulas; adjuvant treatment of diabetic ketoacidosis
.
Sales of terminal somatostatin in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Menet.
com, in 2020, the sales of terminal somatostatin in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) will exceed 2.
4 billion yuan; in 2021H1, its sales will exceed 1 billion yuan , An increase of 2.
46% year-on-year.
From the perspective of manufacturers, Merck's market share was 35.
8%, Jiangsu Coast Pharmaceuticals accounted for 22.
26%, and Hanyu Pharmaceuticals accounted for 12.
36%
.
com, in 2020, the sales of terminal somatostatin in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) will exceed 2.
4 billion yuan; in 2021H1, its sales will exceed 1 billion yuan , An increase of 2.
46% year-on-year.
From the perspective of manufacturers, Merck's market share was 35.
8%, Jiangsu Coast Pharmaceuticals accounted for 22.
26%, and Hanyu Pharmaceuticals accounted for 12.
36%
.
At present, there are 16 manufacturers of somatostatin for injection in the domestic market, and Hanyu Pharmaceutical is the first company to review this product
.
Five companies including Shandong New Times Pharmaceuticals, Hainan Shuangcheng Pharmaceuticals, Jiangsu Coast Pharmaceuticals, Chengdu Shengnuo Biology, and Shanghai Huayuan Pharmaceuticals have submitted supplementary applications for the consistency evaluation of this product
.
.
Five companies including Shandong New Times Pharmaceuticals, Hainan Shuangcheng Pharmaceuticals, Jiangsu Coast Pharmaceuticals, Chengdu Shengnuo Biology, and Shanghai Huayuan Pharmaceuticals have submitted supplementary applications for the consistency evaluation of this product
.
Up to now, Hanyu Pharmaceutical has passed or deemed to have passed the consistency evaluation of 7 varieties, including Thymofaxine for Injection, Carbetocin Injection, Etibatide Injection, and Pramipexole Hydrochloride Sustained Release Tablets , Metformin hydrochloride sustained-release tablets, trimetazidine hydrochloride sustained-release tablets and somatostatin for injection
.
.
Data source: Mi Neiwang database
On November 5, the official website of NMPA showed that Hanyu Pharmaceutical's somatostatin for injection passed the consistency evaluation of generic drugs, which was the first domestic company to pass the evaluation
.
According to data from Mi Nei.
com, in 2020, the sales of terminal somatostatin in public medical institutions in China will exceed 2.
4 billion yuan
.
Up to now, Hanyu Pharmaceutical has been evaluated for 7 varieties
.
.
According to data from Mi Nei.
com, in 2020, the sales of terminal somatostatin in public medical institutions in China will exceed 2.
4 billion yuan
.
Up to now, Hanyu Pharmaceutical has been evaluated for 7 varieties
.
Somatostatin is a cyclic polypeptide hormone.
Somatostatin for injection is mainly used for acute esophageal varices bleeding; severe acute gastric or duodenal ulcer bleeding, or complicated with acute erosive gastritis or hemorrhagic gastritis; pancreatic surgery Prevention and treatment of complications after surgery; adjuvant treatment of pancreatic, biliary and intestinal fistulas; adjuvant treatment of diabetic ketoacidosis
.
Somatostatin for injection is mainly used for acute esophageal varices bleeding; severe acute gastric or duodenal ulcer bleeding, or complicated with acute erosive gastritis or hemorrhagic gastritis; pancreatic surgery Prevention and treatment of complications after surgery; adjuvant treatment of pancreatic, biliary and intestinal fistulas; adjuvant treatment of diabetic ketoacidosis
.
Sales of terminal somatostatin in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Menet.
com, in 2020, the sales of terminal somatostatin in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) will exceed 2.
4 billion yuan; in 2021H1, its sales will exceed 1 billion yuan , An increase of 2.
46% year-on-year.
From the perspective of manufacturers, Merck's market share was 35.
8%, Jiangsu Coast Pharmaceuticals accounted for 22.
26%, and Hanyu Pharmaceuticals accounted for 12.
36%
.
Hospital hospital hospitalcom, in 2020, the sales of terminal somatostatin in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) will exceed 2.
4 billion yuan; in 2021H1, its sales will exceed 1 billion yuan , An increase of 2.
46% year-on-year.
From the perspective of manufacturers, Merck's market share was 35.
8%, Jiangsu Coast Pharmaceuticals accounted for 22.
26%, and Hanyu Pharmaceuticals accounted for 12.
36%
.
At present, there are 16 manufacturers of somatostatin for injection in the domestic market, and Hanyu Pharmaceutical is the first company to review this product
.
Five companies including Shandong New Times Pharmaceuticals, Hainan Shuangcheng Pharmaceuticals, Jiangsu Coast Pharmaceuticals, Chengdu Shengnuo Biology, and Shanghai Huayuan Pharmaceuticals have submitted supplementary applications for the consistency evaluation of this product
.
Enterprise business enterprise.
Five companies including Shandong New Times Pharmaceuticals, Hainan Shuangcheng Pharmaceuticals, Jiangsu Coast Pharmaceuticals, Chengdu Shengnuo Biology, and Shanghai Huayuan Pharmaceuticals have submitted supplementary applications for the consistency evaluation of this product
.
Up to now, Hanyu Pharmaceutical has passed or deemed to have passed the consistency evaluation of 7 varieties, including Thymofaxine for Injection, Carbetocin Injection, Etibatide Injection, and Pramipexole Hydrochloride Sustained Release Tablets , Metformin hydrochloride sustained-release tablets, trimetazidine hydrochloride sustained-release tablets and somatostatin for injection
.
.
Data source: Mi Neiwang database
Data source: Mi Neiwang database 
